Skin Tumour Group National Perspective

Slides:

Advertisements

Similar presentations

Average Earnings by Highest Qualification and Region 2006.

Advertisements

A new approach to offering MS Support – how and when it will come to you.

Understanding Diabetes Dr Gill Hood North Thames Clinical Research Network Barts Health NHS Trust

Healthcare Science Coding Exercise Transition from ‘T’ to ‘U’ Occupation Codes Dec '14 GroupT - HeadcountU - Headcount% EAST MIDLANDS LETB 92,

Cancer Summit Plymouth Hospitals NHS Trust 12 th February 2015 Ruth Bridgeman - Programme Director, National Peer Review Programme.

SW Clinical Senate Emergency Surgical Data. SW wide data.

RCN Customer Feedback. Department/BoardNumber of Complaints Number of complaints per 10,000 members RCN Scotland82.0 RCN Wales31.3 RCN Northern Ireland53.6.

Geography of England Martina Kučerová. 2 Map of England.

Progress in Geography Cara Courage, Head of Learning, Architecture Centre Network Janet Clark, Head of Learning, The Building Exploratory.

Northern Oesophago-Gastric Cancer Unit MDT meeting NECN Audit day 2012 Helen Jaretzke, Angie Tate, Jon Shenfine, Paula Brookes, Leigh-Anne Phillips, Gillian.

LTFT Forum 2015 Results from National Training Survey (NTS)

Delivering clinical research to make patients, and the NHS, better Gynaecology SSG Sept 2015 Research Jenny Forrest, Sub Specialty Lead Wendy Cook, Research.

Delivering clinical research to make patients, and the NHS, better Breast SSG Sept 2015 Research Duncan Wheatley Clinical and Sub Specialty Research Lead.

Delivering clinical research to make patients, and the NHS, better Colorectal SSG March 2015 Research Wendy Cook, Research Delivery Manager dd/mm/yyyy.

Lung Cancer Research Clinical Research Network South West Peninsula Julie Cunningham Research Delivery Manager Oncology / Haematology / Genetics 1.

NMDT (%)Path (%)NOS (%)CNS (%) Weston Area Health  70.5  5.7  66.3  Yeovil District Hospital  54.9  22.9  82.9  University Hospitals.

Delivering clinical research to make patients, and the NHS, better Upper GI SSG March 2015 Research Wendy Cook, Research Delivery Manager dd/mm/yyyy.

Green Flag Award Winners England Wales6165 Scotland5068 Northern Ireland2035 Channel Islands-2 Germany12 The Netherlands68.

Urological Tumour Group National Perspective Data from Portfolio ODP – Cut off 23/10/15 Includes data from Bladder, Prostate, Testis, and Renal CSG Portfolios.

Delivering clinical research to make patients, and the NHS, better Urology SSG 22nd April 2015 Research Wendy Cook, Research Delivery Manager Dr Mohini.

Carlos Rocha Registry Manager National Cancer Registration Service (South West) West Dean Registration Improvement of Non-Melanoma skin cancer.

Delivering clinical research to make patients, and the NHS, better Sarcoma SSG 21 st October 2015 Research Surgeon Captain Professor, Rory Rickard Wendy.

Two-week wait referrals for malignant melanoma: A clinical audit carried out across four UK Cancer Networks South West Cancer Intelligence Service

Teenage conceptions: progress Anglia and Essex 2Teenage conceptions: progress Percentage change in under 18 conception rate

CHD - Waiting Lists Summary Analysis April August 2008 Dr Stephen Green DH Vascular Programme October 2008.

Region At Least One Account Yorkshire & Humber15 / 15 West Midlands14 / 14 East Midlands8 / 9 North East7 / 12 North West20 / 23 East of England11 /

TRIAL PARTICIPATION IN THE OVER 60s: A RE-AUDIT OF THE MANAGEMENT OF AML IN THE SOUTH WEST OF ENGLAND South West Cancer Intelligence Service

Delivering clinical research to make patients, and the NHS, better Skin SSG – Research 18 th June 2015 Dr Toby Talbot, Consultant Oncologist Wendy Cook,

Delivering clinical research to make patients, and the NHS, better Head & Neck SSG Research – 2015/16 30/04/2015 David Hwang Consultant Oncologist Wendy.

httpwww.youtube.com/watch?v=DhxD6sVQEYc:// The Drug Discovery Process.

Diabetes Research Network Professor Azeem Majeed Imperial College, London.

Surrey Health Partners 1 Surrey Clinical Trials Unit What does it mean for you? Royal Surrey County Hospital NHS Foundation Trust Ashford & St Peters’

SWAG Network Gynae SSG Clinical Trials Update June 2016 Dr Rebecca Bowen Consultant Medical Oncologist Royal United Hospital Bath RXUKBRCA00028dDate of.

Pay per event stand prices – providers

SWAG SSG Skin Meeting Thursday 22nd September 2016 Maxine Taylor

Mark Foster Replace this photo with your own by going to Insert  Photo  Picture from File.

SWAG SSG Skin Cancer Meeting

SWAG SSG Head and Neck Cancer Meeting

Skin Cancer Research Report SWAG SSG Maxine Taylor Senior Research Delivery Manager 17/05/2016.

Breast Cancer Research Report SWAG Site Specific Group

Alison Copp Head of Professional Development

SWAG SSG Breast Cancer Meeting

Statutory regulation Department of Health planned to transfer specialists from UKPHR to HCPC - but has postponed legislation If Specialist register transferred.

SWAG SSG Upper GI Cancer Meeting

SWAG SSG Skin Cancer Meeting Tuesday 22nd May Research Report

SWAG SSG Haematology and Lymphoma Meeting

Website Information Website Information

SWAG SSG Colorectal Meeting

SWAG SSG Haematology and Lymphoma Meeting

SWAG SSG Sarcoma Cancer Meeting

SWAG SSG Gynaecology Cancer Meeting

SWAG SSG Colorectal Cancer Meeting

100,000 Genomes Haematolgical Malignancies Update

Program Goals Introduction Case 1: A 44-Year-Old Woman.

SWAG SSG Lung Cancer Meeting

SWAG SSG Gynaecological Cancers Meeting

Breast SSG 11th March 2015 Research Wendy Cook, Research Delivery Manager dd/mm/yyyy.

SWAG SSG Skin Cancer Meeting

SWAG SSG Head and Neck Cancer Meeting

SWAG SSG Sarcoma Meeting

Haematological malignancies – creating new clinical pathways for WGS

Your Stories Shared: The Impact Toolkit

NHS MENTAL HEALTH TRUSTS

SWAG SSG Skin Cancer Meeting Wednesday 23rd May Research Report

58 NHS MENTAL HEALTH TRUSTS

SWAG SSG Lung Cancer Meeting

SWAG SSG Brain Cancer Meeting

National Oesophago-Gastric Cancer Audit

Somerset, Wiltshire, Avon & Gloucestershire Cancer Alliance

58 NHS MENTAL HEALTH TRUSTS

Presentation transcript:

Skin Tumour Group National Perspective Data from Portfolio ODP – Cut off 11/10/15

Skin Tumour Group National Perspective Network 2014/2015 2015/2016 Commercial Non-Commercial Total Rank East Midlands 9 12 21 11 14 Eastern 56 27 83 2 30 Greater Manchester 8 6 23 4 Kent, Surrey and Sussex 3 7 1 13 North East and North Cumbria North Thames 10 17 15 5 North West Coast 63 76 North West London South London 42 44 South West Peninsula 19 Thames Valley and South Midlands 28 25 Wessex 34 West Midlands West of England 31 33 Yorkshire and Humber 219 253 53 57 Data from Portfolio ODP – Cut off 11/10/15

Skin Tumour Group Open Studies Study EM E GM KSS NE&NC NT NWC NWL SL SWP TV&SM Wes WM WoE Y&H CANC - 3574 - Nivolumab for Subjects with Histologically Confirmed Stage III or Stage IV Melanoma 8 12 6 10 2 4 CANC - 3828 VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE MALIGNANCIES 1 3 EORTC 18081 - Adjuvant Pegylated Interferon in Ulcerated Melanoma Head and neck skin malignancy 57 MelMarT - Melanoma Margins Trial - Pilot Study 30 7 5 NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma 13 NCRN567 COLUMBUS: LGX818 +/- MEK162 vs vemurafenib in BRAF V600 melanoma Paclitaxel +/- GSK1120212 or Pazopanib in Melanoma - PACMEL 14 21 SPOT Trial 18 27 UKMCC-01 9 UNITI (Version 2.1) 42 Vitamin D & Immunity Study. Version 3.0 266 WBRT post local treatment in melanoma study Data from Portfolio ODP – Cut off 11/10/15

Skin Tumour Group SWP Recruitment Data from Portfolio ODP – Cut off 11/10/15

Skin Tumour Group SWP Recruitment Trust 2014/2015 2015/2016 Commercial Non-Commercial Total Northern Devon Healthcare NHS Trust Plymouth Hospitals NHS Trust 4 Royal Cornwall Hospitals NHS Trust 11 Royal Devon and Exeter NHS Foundation Trust 1 2 Taunton and Somerset NHS Foundation Trust 3 Torbay and South Devon NHS Foundation Trust Yeovil District Hospital NHS Foundation Trust Data from Portfolio ODP – Cut off 11/10/15

Skin Tumour Group RAG Report Acronym UKCRNID Study Type Trust Investigator Name Recruitment End Date Planned Target Recruitment (Edge) RTT CANC-3574 - Nivolumab (BMS-936558) in Stage III (unresectable) or stage IV Melanoma (CA209-172) 17463 Commercial RCHT Talbot, Dr Toby 22-Dec-19 3 83 NCRN398 IMAGE: Observational Study in Patients with Unresectable or Metastatic Melanoma 12088 28-Mar-15 54 27 -69 NCRN492 - NEMO-MEK162 vs Dacarzabine in NRAS mutation postive melanoma patients 13665 31-Mar-15 -43 UKMCC-01 13736 Non-Commercial RD&E Goodman, Dr Andrew 01-Aug-19 2 1 19 T&S Barthakur, Urmila -30 Data from EDGE– Cut off 06/10/15